Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the follow-on offering of 8,050,000 shares of common stock of NeoGenomics, Inc. for total gross proceeds of approximately $171 million. The common stock is listed on the Nasdaq Global Select Market under the symbol “NEO.”
NeoGenomics specializes in cancer genetics testing and information services. NeoGenomics provides one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. NeoGenomics’ Pharma Services division serves pharmaceutical clients in clinical trials and drug development. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks and managed care organizations throughout the United States.
The Davis Polk corporate team included partner Alan F. Denenberg and associate Jacqueline Marino. The intellectual property and technology team included partner Frank J. Azzopardi and associates Christopher C. Woller and Yifu Chen. Partner Michael Farber and associate Yixuan Long provided tax advice. Members of the Davis Polk team are based in the Northern California and New York offices.